CEO Message

Message from CEO

To Our Valued Supporters

At the Board of Directors meeting held on July 14, 2025, I was appointed Representative Director and CEO of CellSource, once again assuming responsibility for leading the Company. Since its founding, CellSource has pursued the challenge of realizing the practical application of regenerative medicine in society. As the Company’s founder, I am now returning to the forefront of management with a renewed determination to accelerate this mission.

I recognize that CellSource’s business performance has been stagnant and that we have not fully met the expectations of our shareholders. Overcoming this difficult phase and putting the Company back on a solid growth trajectory is my responsibility as its founder.

To that end, we will make strategic investments aimed at solidifying our future earnings foundation rather than focusing solely on short-term profits. Under our business domain of Wellness & Longevity, we will drive healthcare innovation that extends from medical fields to consumer applications, with evidence-based regenerative medicine at its core.

Our key areas of focus are as follows:
First, we will support the introduction of self-funded treatments in orthopedics. In this field, where we have been strengthening our efforts, we aim to go beyond simply providing contract processing services by further enhancing our support framework to make it easier for medical institutions to adopt self-funded treatments. By leveraging physical therapists and promoting the integration of regenerative medicine expertise into clinical practice, we will further reinforce our support structure and work to steadily increase contract processing orders. We consider this initiative essential for ensuring the sustainability of Japan’s healthcare system in a super-aged society.

Second, we will expand value-added medical services. Areas such as anti-aging, anti-chronic inflammation, and the rapidly growing aesthetic medicine sector represent global growth markets with rising demand. Leveraging our R&D capabilities in cell culture and the technological advantages we have developed, we aim to lead in these areas and cultivate new pillars of growth.

Third, we will strengthen our inbound medical services. As we welcome patients from overseas, we will enhance our branding based on solid clinical evidence and rigorous quality control to build enduring trust. Through these efforts, CellSource will serve as a bridge connecting Japanese medical institutions with patients worldwide, delivering advanced treatments originating in Japan to the global stage.

While these initiatives may require concentrated investment in the short term, I am confident they are essential for achieving sustainable growth and reinforcing our earnings foundation.

CellSource now stands at the threshold of its next stage of growth. We will strive to deliver medical care that closely supports each individual patient and create a future where more people can benefit from advanced medical technologies. Building on the solid foundation we have established in Japan, we will expand our technologies and expertise globally, contributing to the advancement of regenerative medicine worldwide. We at CellSource will remain committed to taking on new challenges and delivering lasting, meaningful value to society.

We sincerely ask for your continued support and understanding.